Interactions between host plasminogen (Plg) and streptokinase (SK) secreted by group A streptococci (GAS) have been hypothesized to promote bacterial invasion of tissues. The virulence of GAS strain UMAA2616, after being subcutaneously inoculated into mice, was studied. Skin lesions and mortality were observed after inoculation of cfu. Coadministration of human Plg with UMAA2616 markedly increased virulence. Group A streptococci (GAS) are important human pathogens that cause diseases ranging from mild pharyngeal and skin infections to potentially fatal disorders such as necrotizing fasciitis and toxic shock syndrome [1] . The ability of GAS to cause disease depends on its ability to invade host tissues and to evade host defense mechanisms. Relatively little is known with regard to the specific mechanisms underlying streptococcal spread through tissues. The plasminogen (Plg)-activation system appears to play a major role in regulating the migration of mammalian cells during processes such as wound repair and angiogenesis [2] . Several mammalian cell types express receptors for urinary-and tissue-type Plg activators.
Group A streptococci (GAS) are important human pathogens that cause diseases ranging from mild pharyngeal and skin infections to potentially fatal disorders such as necrotizing fasciitis and toxic shock syndrome [1] . The ability of GAS to cause disease depends on its ability to invade host tissues and to evade host defense mechanisms. Relatively little is known with regard to the specific mechanisms underlying streptococcal spread through tissues. The plasminogen (Plg)-activation system appears to play a major role in regulating the migration of mammalian cells during processes such as wound repair and angiogenesis [2] . Several mammalian cell types express receptors for urinary-and tissue-type Plg activators.
These enzymes convert Plg to plasmin, a broad-spectrum serine protease that facilitates cell migration by degradation of extracellular components-such as fibrin, laminin, and fibronectin-and by activation of latent matrix metalloproteinases [3] . Several lines of evidence suggest that GAS may use related mechanisms to migrate through host tissues. GAS secrete streptokinase (SK), a potent activator of host Plg [4] . Plg-binding proteins have been identified on the surface of GAS [5] [6] [7] [8] . Plasmin formation has been detected on the surface of GAS in vitro [9] , and GAS-bound plasmin is resistant to inactivation by a 2 -antiplasmin [9] .
Consequently, it has been postulated that, by facilitating invasion of host tissues, SK-Plg interactions play a key role in streptococcal virulence. However, the data leading to this hypothesis have been generated predominantly in vitro, and no studies have adequately examined, in vivo, the impact of SK-Plg interactions on GAS invasiveness. Furthermore, it is unknown whether host Plg can support streptococcal invasiveness by SK-independent pathways. To address these issues, we generated SK-deficient GAS, by gene targeting, and, in a murine skin-infection model, compared the virulence of SK-producing and SK-deficient GAS. We also examined the role that Plg plays in virulence of GAS, by coadministering bacteria with purified Plg or Plg derivatives. Our results suggest that Plg plays an important role in the promotion of virulence of GAS and that this effect is mediated by both SK-dependent and SK-independent pathways.
MATERIALS AND METHODS
Reagents. Glu-Plg was purified from human plasma by lysine-Sepharose chromatography [10] . Mini-Plg (kringle 5 and protease domains) was prepared by elastase digestion of GluPlg and was isolated by gel filtration and lysine-Sepharose chromatography, as described elsewhere [11] . Glu-Plg and miniPlg were incubated with D-Phe-Phe-Arg-chloromethylketone trifluoroacetate (Calbiochem-Novabiochem), a plasmin inhibitor, and were dialyzed extensively before use. Plasmin was prepared by incubating 4 mmol Plg/L with 2 mmol urokinase/ L for 4 h at room temperature. Active-site-blocked plasmin was prepared by incubating 30 mg of plasmin with 4 mg of D-Val-L-Phe-L-Lys CH 2 Cl for 4 h at room temperature [12] then exhaustively dialyzing the reaction mixture against 0.05 mol Tris-HCl/L, 0.02 mol lysine/L, 0.1 mol NaCl/L, 0.01 mol EDTA/L (pH 8.8). Fluorescein-labeled Glu-Plg was prepared as described elsewhere [13] .
Bacteria. GAS strain MGAS166 is a streptomycin-resistant type-M1 isolate derived from a case of invasive streptococcal disease [14] ; GAS strain UMAA2616 (previously designated as UMAA2392 [14] ), which exhibits enhanced expression of SK and other virulence factors, was derived from MGAS166 by sitedirected deletion in the csrR gene. Streptococci were cultured in Todd-Hewitt broth containing 0.2% yeast extract (THY; Difco) or on Todd-Hewitt yeast-extract agar (THYA) plates that were supplemented with appropriate antibiotics. To generate an SKdeficient isogenic strain of UMAA2616, UMAA2616 was transformed by electroporation with pJRS233ska::QKm [6] , which contains a temperature-sensitive origin of replication and a kanamycin-resistance cassette (QKm-2), flanked by 5 and 3 portions of the SK gene, respectively (provided by M. Svensson, Lund, Sweden). Transformants were identified by their ability to grow at 30ЊC on THYA containing erythromycin. Clones that underwent the intended recombination events were selected by use of temperature-and antibiotic-based strategies [6] and were confirmed by polymerase chain reaction (PCR) analysis of chromosomal DNA, as described elsewhere [15] .
Western-blot test. A culture of bacterial cells that had been incubated overnight was centrifuged, and the broth was removed. Bacterial pellets were resuspended in 2.5% SDS, were boiled, were subjected to SDS-PAGE (under reducing conditions), and were transferred to polyvinylidene diflouride membranes. Blocked membranes were incubated with human anti-SK polyclonal antibody overnight at 4ЊC, were incubated with peroxidase-conjugated anti-human IgG (Sigma) for 1 h at room temperature, and were developed with the Boehringer Mannheim chemiluminescence Western-blotting kit.
Fibrin zymography. Bacterial lysates were subjected to nonreducing SDS-PAGE. Gels were gently agitated with 1.5% Triton X-100 for 1 h at room temperature, to remove SDS, and were placed on a 1.5% agarose gel containing 5.6 mg of Plg/ mL, 2 mg of bovine fibrinogen/mL, and 0.1 U of thrombin/ mL. The zymogram was photographed after incubation for 2 h at 37ЊC.
SK-activity assay. Five microliters of conditioned media from a culture of bacterial cells that had been incubated overnight was added to 96-well microtiter plate wells containing 60 mg of Glu-Plg/mL and 300 mmol H-D-Val-Leu-Lys-p-nitroanilide/L (S2251) in 0.01 mol Tris-HCl/L, and 0.14 mol NaCl/L (pH 7.5; reaction volume, 100 mL). Absorbance at 405 nm (A 405 ) was measured every 30 s for 30 min.
Clot-lysis assay. GAS were added to 0.5 mL citrated, human plasma, and clot formation was induced by addition of 5 mmol CaCl 2 /L and 2 U of thrombin/mL. Clots were incubated at 37ЊC, and the time required for complete clot lysis to occur was recorded.
Measurement of human Plg in murine plasma. Five microliters of citrated murine plasma was added to 75 mL of Trisbuffered saline containing 1.33 mmol recombinant SK/L. After the reaction mixture was incubated for 10 min at room temperature, 20 mL of S-2251 was added, to attain a final concentration of 300 mmol/L. The A 405 of reaction mixtures was measured in a microtiter-plate reader every 30 s for 30 min. A standard curve was constructed from murine plasma samples containing increasing concentrations (0-2.4 mmol/L) of purified human Plg. Control reactions revealed that, under these experimental conditions, murine plasma (i.e., plasma lacking human Plg) generated essentially no detectable amidolytic activity.
Binding of Plg to bacteria. An overnight culture of UMAA2616 was centrifuged, and the pellet was washed 3 times in PBS containing 0.1% bovine serum albumin, 0.01% Tween 80, and 0.02% sodium azide. The absorbance of the cell suspension at 600 nm was measured, and the cell density was adjusted to cells/mL; 0.08 mmol fluorescein-labeled Glu- 8 2 ϫ 10 Plg/L was added to 1 mL of the bacterial suspension in the absence or presence of either unlabeled Glu-Plg, unlabeled active-site-blocked plasmin, or unlabeled mini-Plg (each at 1.6 mmol/L). After 30 min at 37ЊC, cells were washed 3 times and were resuspended in 1 mL of PBS containing 0.1% bovine serum albumin, 0.01% Tween 80, and 0.02% sodium azide. Fluorescence of cell suspension was measured in a fluorometer (excitation wavelength, 490 nm; emission wavelength, 515 nm) that was calibrated with washed UMAA2616 that had not been exposed to labeled Plg.
Murine skin-infection model. Four-week-old hairless male crl:SKH1(hrhr) Br mice (Charles River) were inoculated with streptococci, in subcutaneous tissue of the dorsal aspect of the right flank. Mice were weighed daily for 4 days after inoculation. Skin lesions were measured daily by a caliper. Lesion area was calculated by the following equation:
where L is the long axis of the lesion, and W is the short axis of the lesion [14] . Measurements were made by an observer who was unaware of the inoculum. All animal-care and experimental procedures complied with US National Institutes of Health guidelines and were approved by the University of Michigan Committee on Use and Care of Animals. To ensure that there was equal inocula of comparator strains, midexponential cultures of streptococci, harvested at an absorption at 600 nm (A 600 ) of ∼0.6, were used for all experiments. Inocula were standardized by absorbance rather than by colony-forming units (cfu), to avoid inequalities associated with variations in streptococcal chain length, which might affect quantification by plating. However, standard growth curves obtained by plating broth cultures of strain UMAA2616 or MGAS166, at frequent intervals, were found to be highly reproducible. Consequently, all cultures harvested at A 600 of 0.63-0.65 reliably yielded cfu/mL and could be diluted 8.6-200-fold in 8 3 ϫ 10 ice-cold THY broth, to prepare 0.2-mL inocula ranging from to cfu, respectively, as required by experimental 5 6 3 ϫ 10 7 ϫ 10 design. In a typical experiment, 5-10 mice were inoculated with a single bacterial suspension. As indicated, purified human Plg or active-site-blocked plasmin was added to some bacterial suspensions immediately before inoculation. For some experiments, mice received either 20 mg of human Plg/kg/d or an equal volume of vehicle, administered via ventral intraperitoneal (ip) injection, for 3-4 days before bacterial inoculation, on the day of inoculation, and for 1-3 days after inoculation. In experiments designed to examine the effect that plasmin inhibition has on bacterial virulence, mice were inoculated with UMAA2616 cfu/mL and 2 mg human Plg, in the ab-5 3 ϫ 10 sence or presence of 1.2 mg D-Phe-Phe-Arg-chloromethylketone trifluoroacetate, an irreversible plasmin inhibitor. Statistical analysis. Data were expressed as mean ‫ע‬ SE. Survival between groups was compared by proportional-hazards analysis performed by use of SAS, version 8.0 (SAS Institute). Differences in survival were compared by log-rank test. Body weight and skin-lesion area were analyzed by Student's t test, the Mann-Whitney rank-sum test, or 1-way analysis of variance. The Bonferroni test was used for comparisons between multiple groups.
RESULTS

Generation and characterization of SK-deficient GAS. SKdeficient UMAA2616 (UMAA2616-SK
Ϫ ) was generated from the parent strain by plasmid-insertional mutagenesis of the SK gene, as described elsewhere [6] . Amplification of UMAA2616-SK Ϫ DNA-with oligonucleotide primers complementary to the 5 and 3 portions of the SK gene, respectively, or to the SK-gene-interrupting QKm-2 cassette flanked by 5 or 3 portions of the SK sequence-yielded the predicted PCR products (figure 1A and 1B). SK was detected by Western-blot analysis of UMAA2616 cell lysates but was not detected in lysates of UMAA2616-SK Ϫ ( figure 1C ). Fibrin zymography revealed no detectable Plg-activator activity in lysates of UMAA2616-SK Ϫ ( figure 1D ). Plg-activator activity was readily detectable in conditioned media from UMAA2616, but not in that from UMAA2616-SK Ϫ (data not shown). Log-phase growth rates at 37ЊC did not differ between UMAA2616 and UMAA2616-SK Ϫ (data not shown).
Comparison of virulence of UMAA2616 and that of UMAA2616-SK
5
. By 24 h after inoculation with cfu 6 7 ϫ 10 of UMAA2616, mice developed skin lesions that were characterized by induration and erythema. By 2 days after inoculation, the central portion of the lesion became necrotic (figure 2), and the area of necrosis gradually enlarged during the next several days. To determine the impact that SK deficiency has on streptococcal virulence, mice were inoculated with 6 7 ϫ 10 cfu of either UMAA2616 or UMAA2616-SK Ϫ . All 21 mice inoculated with UMAA2616 and all 21 mice inoculated with UMAA2616-SK Ϫ developed skin lesions by 24 h after inoculation. At 24 h after inoculation, the mean area of skin lesions did not differ significantly between groups ( ) (figure P p .96 3A). Mice challenged with UMAA2616-SK Ϫ developed necrotic skin lesions similar in time course and gross appearance to those observed in mice challenged with UMAA2616. At days 2-4, there was a statistically insignificant trend ( ) toward P p .19 larger skin-lesion area in mice inoculated with UMAA2616, compared with that in mice inoculated with UMAA2616-SK Ϫ . In both experimental groups, mean skin-lesion area was reduced on day 4, compared with earlier times, because the mice that died were those with larger skin lesions. Four-day survival was 33% in mice inoculated with UMAA2616 and 52% in mice inoculated with UMAA2616-SK Ϫ ( , figure 3B). During P p .10 the 4 days after bacterial inoculation, no significant differences between groups were observed in body-weight changes (data not shown).
We hypothesized that the lack of a significant effect of SK gene status on bacterial virulence could be due, at least in part, to the relatively strong resistance of murine Plg to activation by SK [16] . To explore this possibility, we purified Plg from human plasma and coadministered it with a smaller inoculum of UMAA2616. Coadministration of 0.1-2 mg of human Plg markedly increased mean skin-lesion area in a dose-dependent fashion (figure 4A), whereas subcutaneous injection of human Plg alone (2 mg) produced no detectable skin lesions (n p mice). In addition, exogenous human Plg enabled smaller 17 ). P p .0001
Coadministration of human Plg increased mortality after bacterial inoculation, in a dose-dependent manner ( figure 4B) .
Coadministration of human Plg with bacteria would be expected to produce high local concentrations of Plg within the per group) were used to both study skin-lesion development and n p 21 survival.
skin. To determine whether high local concentrations of human Plg at the site of inoculation were required to promote bacterial virulence, mice ( ) received 20 mg of human Plg/kg/d, n p 9 administered via ventral ip injection, for 4 days before bacterial inoculation, on the day of inoculation, and 1-2 days after inoculation. Control mice ( ) received an equal volume of n p 9 vehicle at an identical schedule of injections. After inoculation of cfu of UMAA2616, skin-lesion development was 5 3 ϫ 10 markedly enhanced in mice that received human Plg, compared with that in control mice (figure 5). All mice that received human Plg appeared to be ill by 2 days after bacterial inoculation, and 5 of 9 animals died by day 4 after bacterial inoculation. In contrast, none of the 9 mice that did not receive Plg appeared to be ill after bacterial inoculation, and none died. In mice, the plasma concentration of human Plg ( ), after n p 3 5 days of ip injections (20 mg/kg/d), was mg/mL. In 4.1 ‫ע‬ 1.3 comparison, in normal human plasma, the concentration of Plg is ∼180 mg/mL. Therefore, even when administered in a manner that produces low concentrations within plasma and presumably within the skin, human Plg markedly enhances virulence of UMAA2616.
We compared the virulence of UMAA2616 and that of UMAA2616-SK Ϫ ( cfu) when each strain was coadmin-5 3 ϫ 10 istered with 2 mg purified human Plg ( mice/group). n p 28 Under these conditions, UMAA2616 produced significantly larger skin lesions than did UMAA2616-SK Ϫ ( ) (fig-P p .0001 ure 6A). Four-day survival was significantly lower in mice inoculated with UMAA2616 in the presence of human Plg than in those inoculated with UMAA2616-SK Ϫ in the presence of human Plg ( ) ( figure 6B ). At the lower inoculum size P p .018 used in these experiments ( cfu), administration of bac- 5 3 ϫ 10 teria in the absence of human Plg produced negligible skin lesions and no mortality. It is of interest that coadministration of human Plg significantly enhanced skin-lesion development and increased mortality, after inoculation with UMAA2616-SK Ϫ (i.e., compared with mice inoculated with UMAA2616-SK Ϫ alone), although to a lesser extent than was observed with UMAA2616. These results suggest that interactions between Plg and GAS can promote virulence by SK-dependent and SKindependent pathways. In vitro experiments revealed that UMAA2616 bound fluorescein-labeled Plg and that binding of labeled Plg was blocked by unlabeled Plg and active-site-blocked plasmin but not by either mini-Plg or albumin ( figure 7) . However, active-siteblocked plasmin did not promote skin-lesion development when it was coadministered with UMAA2616 ( figure 8 ). These results suggested that mere binding of Plg to bacteria did not promote virulence (e.g., by inducing expression of another virulence factor). Rather, generation of plasmin activity appeared ) or an equal volume of vehicle ( ), via daily intraperitoneal n p 9 n p 9 injections, as described in the text, and were inoculated with UMAA2616 cfu. Mean skin-lesion area was determined for each group on 5 3 ϫ 10 days 1-4 after bacterial inoculation. Numbers near each data point represent the number of surviving mice on that day. This experiment was performed 4 times (with 1-5 mice/group/experiment, yielding a total of 9 mice/each group) with similar results for each experiment. Differences in mean skin-lesion area between groups were statistically significant ( ) on each of days 1-4. P ! .05 to be required to promote bacterial spread. To further test this hypothesis, we inoculated mice with UMAA2616 and human Plg, in the absence or presence of D-Phe-Phe-Arg-chloromethylketone trifluoroacetate, an irreversible plasmin inhibitor. At 1 day after inoculation, skin-lesion development was essentially absent in mice that received the plasmin inhibitor (mean lesion area, mm 2 ; ), whereas control mice developed 0.78 ‫ע‬ 0.78 n p 3 extensive, necrotic lesions (mean lesion area, mm 2 ; 333 ‫ע‬ 28 ;
). In mice that received the plasmin inhibitor, n p 2 P р .01 there was no significant skin-lesion development by 4 days after bacterial inoculation; 0.1 mmol D-Phe-Phe-Arg-chloromethylketone trifluoroacetate/L had no significant effect on the logphase growth of UMAA2616 in vitro (which was based on 4 experiments; data not shown). In addition, clots that had formed in vitro from citrated human plasma in the presence of cfu of UMAA2616/mL exhibited complete lysis after 5 2 ϫ 10 3 h, whereas plasma clots that had formed in vitro from citrated human plasma in the presence of UMAA2616-SK Ϫ did not exhibit any apparent lysis, even after 18 h of incubation. These results suggest that UMAA2616 induces conversion of Plg to plasmin, under physiologic conditions. Together, these in vivo and in vitro experiments suggest that the virulence of UMAA2616 depends, to a significant extent, on its capacity to induce plasmin formation.
Effect that exogenous human Plg has on virulence of MGAS166. We used streptococcal strain UMAA2616 in the experiments described above because, in mice, it reproducibly induces the formation of necrotic skin lesions after subcutaneous inoculation. To determine whether exogenous human Plg enhances the virulence of a clinical streptococcal isolate, mice ( ) were inoculated with cfu of MGAS166 6 n p 15 7 ϫ 10 in the presence of human Plg (0.4 mg coadministered subcutaneously with bacteria and 20 mg/kg/d administered by ip injection, for 3 days before bacterial inoculation, on the day of inoculation, and for 3 days after inoculation). Control groups consisted of (1) 15 The same mice were used to study both skin-lesion development and survival. ). Extensive skin lesions involving a large portion of the .21 flank and characterized by extensive skin necrosis subsequently developed in 3 (20%) of 15 mice that received MGAS166 in the presence of human Plg. Such lesions were not observed in the 15 control mice that received subcutaneous MGAS166 and ip saline injections. Control mice that received 5 daily ip injections of human Plg ( ) appeared healthy and did not n p 4 develop skin lesions. By 5 days after inoculation with MGAS166, 7 (47%) of 15 mice that received human Plg died versus 1 (6.7%) of 15 control mice that received MGAS166 and ip saline injections ( , figure 9) . Taken together, these results suggest P p .02 that interactions with host Plg also enhance the virulence of MGAS166.
DISCUSSION
The goal of this study was to modulate SK-Plg interactions in vivo, to examine their role in promotion of streptococcal invasive potential. The main findings of our experiments are that (1) SK promotes virulence of GAS (i.e., the development of skin lesions and the progression to lethal infection), (2) the virulence-enhancing effect of SK appears to depend on the generation of plasmin activity, and (3) Plg can promote virulence of GAS, not only by interacting with SK, but also by an SK-independent pathway or pathways.
We have found that expression of SK by UMAA2616 (at an inoculum size of cfu) did not have a significant effect 6 7 ϫ 10 on virulence. However, coadministration of purified human Plg with UMAA2616 reduced by 120-fold the inoculum size that was required to consistently generate skin lesions in mice. Expression of SK by UMAA2616 in the presence of exogenous human Plg had a marked effect on bacterial invasion of host tissues and on mortality. The lack of a significant effect of expression of bacterial SK in the absence of exogenous human Plg is consistent with studies demonstrating that murine Plg is highly resistant to activation by SK [16, 17] . The potent effect that SK has on virulence of UMAA2616 in the presence of human Plg, but not in its absence, supports a key role for SK-Plg interactions in virulence of GAS. Unlike human Plg, murine Plg and Plg of many other mammals that are commonly used in laboratory research (e.g., rats, rabbits, pigs, and dogs) are resistant to activation by SK [17] . In addition, allelic variation of both the SK gene and the corresponding protein may play a key role in modulation of SK-Plg interactions, species specificity, and streptococcal virulence [18, 19] . Our observation that purified human Plg renders a normally GAS-resistant animal, the mouse, mark- Figure 8 . Effect of Glu-plasminogen (Plg) versus active-site-blocked (ASB) plasmin, on virulence of group A streptococci (GAS). Mean skinlesion area was measured 24 h after inoculation with cfu of 5 3 ϫ 10 either UMAA2616 alone ( mice), UMAA2616 coadministered with n p 24 10 nmol ASB plasmin ( mice), or UMAA2616 coadministered with n p 11 10 nmol Glu-Plg ( ). Each experiment was performed 2-4 times n p 12 (with ∼6 mice/group/experiment), with similar results for each experiment. Nineteen of 24 mice in the UMAA2616-alone group were from the Plg 0-mg group presented in figure 4 . * , vs. UMAA2616/ASB-P 1 .05 plasmin; ** , vs. other 2 groups. P ! .05 Figure 9 . Survival after subcutaneous inoculation with MGAS166. Mice received purified human plasminogen (Plg) or vehicle, as described in the text, and were inoculated with cfu of MGAS166. This experiment 6 7 ϫ 10 was performed 3 times (with 4-6 mice/group/experiment, yielding a total of 15 mice/group) with similar results for each experiment.
edly more sensitive to GAS infection supports the hypothesis that the relatively strict human pathogenicity of GAS may be due, in part, to the uncommon sensitivity of human Plg to activation by SK.
We have found that purified human Plg enhanced the virulence of UMAA2616-SK Ϫ (although to a lesser extent than that with the parental, SK-producing strain). These results suggest that SK-Plg interactions enhance virulence of GAS but that Plg can also promote invasiveness by an SK-independent mechanism or mechanisms. The lack of detectable Plg-activator activity in lysates prepared from UMAA2616-SK Ϫ suggests that production of another Plg activator by GAS did not account for the SKindependent effect of Plg. Active-site-blocked plasmin bound to UMAA2616 but did not promote virulence. In addition, a plasmin inhibitor markedly suppressed virulence of UMAA2616. These results suggest that activation of Plg to plasmin is required to promote bacterial invasion of host tissues and that mere binding of Plg to GAS, which occurs via kringles 1-3 [20] , does not significantly activate a signaling pathway that triggers expression of other virulence factors. A previous study has shown that tissuetype Plg activator activates Plg much more rapidly when it is bound to stroptococci, compared with when it is free in solution [21] . Therefore, it is possible that activation of Plg, by host tissueor urinary-type Plg activators, may have accounted for the capacity of Plg to enhance virulence of GAS, in the absence of SK. To our knowledge, our results provide the first in vivo data to support the hypothesis that interactions between host PAs and Plg, on the surface of GAS, may play an important role in streptococcal-tissue invasiveness, as proposed by Kuusela et al. [21] . It is possible that this alternate pathway of plasmin generation may be more important in hosts with high anti-SK antibody titers due to previous streptococcal infection. We used streptococcal strain UMAA2616, including the SKdeficient isogenic strain, in most of our experiments because it reproducibly induces progressive, necrotic skin lesions in mice, thereby facilitating an analysis of the role that streptococcal-Plg interactions play in bacterial virulence. UMAA2616 contains a targeted null mutation in the csrR gene, 1 component of a regulatory system (CsrR/CsrS) that represses the expression of several virulence factors, including SK, hyaluronic acid capsule, streptolysin S, and SpeB [14, [22] [23] [24] . Spontaneous mutations in this regulatory locus are a regular feature of necrotic murine skin infections and have been observed in human isolates [14, 25] . Therefore, the choice of a csrR mutant as the test strain in our model system is not entirely artificial. However, we cannot infer from our studies with this mutant that the role of streptococcal-Plg interactions in bacterial virulence can be generalized to GAS strains with an intact CsrR/CsrS regulatory system. Nevertheless, we have found that administration of human Plg to mice significantly enhances mortality after subcutaneous inoculation with MGAS166, a clinical isolate with normal CsrR/CsrS function. Although additional experiments are necessary to better define the effects that Plg has on the virulence of GAS strains with normal CsrR/CsrS function, our studies of MGAS166 support the relevance of our results with UMAA2616 to other GAS strains. An alternative strategy to study the in vivo role of bacterial-Plg interactions in virulence of GAS is to compare the invasive potential of GAS in Plg-deficient (Plg Ϫ/Ϫ ) mice versus that in wild-type mice, as was done by Li et al. [26] , who preincubated GAS with human plasma and purified SK and then studied mouse survival after injection of high concentrations (10 8 cfu) of pretreated bacteria into a skin air sac. No significant difference in survival was observed between wild-type mice and Plg Ϫ/Ϫ mice. However, the enhance-ment of virulence (i.e., increase in mortality) by plasma/SK pretreatment was reported to be greater in wild-type mice than in Plg Ϫ/Ϫ mice, on the basis of comparisons to historical control groups of wild-type mice and Plg Ϫ/Ϫ mice that were inoculated with bacteria not pretreated with plasma and purified SK. A limitation to the use of Plg Ϫ/Ϫ mice to study the role of Plg in virulence of GAS is that, although Plg is present in control (i.e., wild-type) mice, it is resistant to activation by SK [16] . Therefore, with regard to SK function, differences between Plg Ϫ/Ϫ mice and wild-type mice may be minimal. In addition, Plg Ϫ/Ϫ mice are smaller and have decreased survival, compared with wild-type mice, as a result of widespread deposition of fibrin in organs [27, 28] . These baseline differences in general health, between wild-type mice and Plg Ϫ/Ϫ mice, hinder the ability to compare their responses to bacterial infection [29] . In comparison, our experiments involved the administration of exogenous human Plg to mice. This approach allows comparison of experimental animals with readily activatable Plg versus those with poorly activatable Plg, avoids differences in general health between experimental groups, and obviates the need for pretreatment of bacteria with exogenous SK before inoculation. In summary, our study strongly suggests that GAS-Plg interactions play a key role in promoting bacterial-tissue invasiveness in vivo. It also suggests that both bacterial SK and host Plg activators promote virulence of GAS by catalyzing plasmin formation and supports the hypothesis that the selectivity of SK for human Plg is a major determinant of the relatively strict human pathogenicity of GAS. Finally, it is possible that therapeutic strategies aimed at disrupting GAS-Plg interactions could prove to be useful in the treatment of streptococcal infections.
